PPARα activation is known to improve steatosis and inflammation in pre-clinical models of NAFLD, whereas mice lacking hepatocytic PPARα develop hepatic steatosis and patients with NAFLD display reduced expression of PPARα23,36. This evidence concerns the gene PPARA and fatty liver disease.